维普期刊资源整合服务平台（V6.5）

34篇 您的检索式：作者名="Hollak"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	An evidence-based review of the potential benefitsof taliglucerase alfa in the treatment of patients with Gaucherdisease显示文摘	Hollak CE	2012	Core Evid2012，7，：	1
2	Ma-rked elevation of plasma chitotriosidase activity:a novel hallmark of Gaucher disease显示文摘	Hollak CE Van Weely S Van Oers MH	1994	J Clin Invest1994，93，：	1
3	European ordinance on orphan drugs:changes and threats显示文摘	Linthorst G Hollak C	2003	Ned Tijdschr Geneeskd2003，147，4：	1
4	Plasma and metabolic abnormalities inGaucher's disease显示文摘	Aerts JM Hollak CE	1997	Baillieres Clin Haematol1997，10，4：	1
5	Marked elevation of plasma ehitotriosidase activity: a novel hallmark of Gaueher disease 显示文摘	Hollak C E van Weely S van Oers M H	1994	J Clin Invest1994，93，3：	1
6	Gaucher disease:from fundamental research to effective therapeutic interventions显示文摘	De Fost M Aerts JM Hollak CE		0，，01：	1
7	Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaueher disease: a prospective, open-label, non-inferiority study显示文摘	COX TM AMATO D HOLLAK CEM	2012	Orphanet J Rare Dis2012，7，：	1
8	Miglustat thera- py in type 1 Gaucher disease: clinical and safety outcomes in a multicenter retrospective cohort study 显示文摘	KUTER DJ MEHTA A HOLLAK CEM	2013	Blood Cell Mol Dis2013，51，2：	1
9	The clinical spectrum and pathophysi- ology of skeletal complications in lysosomal storage disorders 显示文摘	CLARKE L A HOLLAK C E	2015	Best Pract Res Clin Endocrinol Metab2015，29，2：	1
10	Novel oral treatment of Gaucher's disease with N- butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis显示文摘	Cox T Lachmann R Hollak C	2000	Lancet2000，355，9214：	1
11	Substrate reduction therapy of glycosphingolipid storage disorders显示文摘	AERTS J M HOLLAK CE BOOT RG	2006	J Inherit Metab Dis2006，29，：	1
12	Plasma and metabolic abnormalities in Gaucher's disease显示文摘	Aerts JM Hollak CE	1997	Baillieres Clin Haematol1997，10，4：	1
13	Marked elevation of plasma chitotriosidase activity,a novel hallmark of Gaucher disease显示文摘	HOLLAK C E M WEELY S VAN OVES M H J	1994	J Clin Invest1994，93，：	1
14	Marked elevation of plasma chitotriosidase activity: a novel hallmark of Gaucher disease 显示文摘	Hollak CE Weely S Oers MH	1994	J Clin Invest1994，93，：	1
15	Quantification of skeletal involvement in adults with type Ⅰ Gaucher's disease:fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter显示文摘	Maas M Hollak CE Akkerman EM	2002	AJR Am J Roentgenol2002，179，4：	1
16	Small fiber neuropathy in Fabry disease 显示文摘	Biegstraaten M Hollak CE Bakkers M	2012	Mol Genet Metab2012，106，2：	1
17	An evidence-based review of the potential benefits of taliglucerase alfa in the treatment of patients with Gaucher dis- ease显示文摘	HOLLAK CE	2012	CoreEvid2012，7，：	1
18	Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin( OGT 918) to decrease substrate biosynthesis显示文摘	Cox T Laehmann R Hollak C	2000	Lancet2000，355，：	1
19	Marked elevation of plasma chitotriosidase activity: a novel hallmark of Gaucher disease 显示文摘	Hollak CE WS Oers MH	1994	J Clin Invest1994，93，3：	1
20	Enhancingcareerdevelopmentthroughthecareersuccessclub显示文摘	WesselRD NicholasT HollAK etal	2003	JournalofCareerDevelopment2003，29，4：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示